| Literature DB >> 14561081 |
Santiago Conde1, Daniel I Pérez, Ana Martínez, Concepción Perez, Francisco J Moreno.
Abstract
Glycogen synthase kinase (GSK-3beta) plays a crucial role in Alzheimer's disease (AD). Its inhibition is a valid approach to the treatment of AD. In this initial letter, some thienyl and phenyl alpha-halomethyl ketones are described as new non-ATP competitive inhibitors of GSK-3beta. They are considered as lead compounds for designing and synthesizing new series, to carry out SAR studies, clear up the mechanism of action, and, in general, evaluate their therapeutical usefulness.Entities:
Mesh:
Substances:
Year: 2003 PMID: 14561081 DOI: 10.1021/jm034108b
Source DB: PubMed Journal: J Med Chem ISSN: 0022-2623 Impact factor: 7.446